Imeik Technology Investment Quality Review (300896.SZ)

Quality score: 85/100 Valuation position: current price/base FV 1.51 Final signal: WATCHLIST

Core Conclusion

Imeik Technology is WATCHLIST. The 85/100 score is high, but current price of CNY109.00 is above base FV of CNY72.04. Conservative/base/optimistic FV is CNY43.65/CNY72.04/CNY91.49, so valuation discipline keeps the signal from upgrading.

Business And Quality

Five-year revenue CAGR is 14.1%, and latest-year FCF is CNY1.15bn. The score reflects high-margin medical-aesthetics economics, good cash generation, and a net cash balance, while product-cycle, regulation, and evidence depth remain watch items.

Financial Audit

The review uses fiscal 2021-2025 in CNY and a 1.7% CNY 10Y government-bond yield dated 2026-07-31. Five-year FCF/Net Income is 0.91 and OCF/Net Income is 1.00. Latest net cash is CNY0.97bn.

Valuation

Normalized FCF is the anchor, with cash and debt adjusted separately. Price/base FV of 1.51 fails the 0.70 buy gate and does not provide a 2x base-case margin.

Buy And Monitor

Current action is watchlist. Upgrade requires price/base FV below 0.70, quality score of at least 75, and stronger evidence that growth and pricing power are durable. Track revenue trend, FCF/Net Income, ROIC, net cash/debt, dividends, buybacks, and governance disclosure.

Risks

Risks include regulatory pressure, product concentration, competition, medical-aesthetics demand cycles, margin compression, and weaker cash conversion.

Sources

Sources are public quote and financial data platforms, company filings or IR, ChinaBond for the CNY risk-free rate, and public FX data where applicable. Research only, not personalized investment advice.